Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete responsedthe Neo-Runner study

被引:3
|
作者
Garrone, O. [1 ]
Paccagnella, M. [2 ]
Abbona, A. [2 ]
Ruatta, F. [1 ]
Vanella, P. [3 ]
Denaro, N. [1 ]
Tomasello, G. [4 ]
Croce, N. [3 ]
Barbin, F. [1 ]
Rossino, M. G. [1 ]
La Porta, C. A. M. [5 ,6 ]
Sapino, A. [7 ,8 ]
Torri, V. [9 ]
Albini, A. [10 ]
Merlano, M. C. [7 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Med Oncol, Milan, Italy
[2] Translat Oncol ARCO Fdn, I-12100 Cuneo, Italy
[3] S Croce & Carle Teaching Hosp, Dept Med Oncol, Cuneo, Italy
[4] ASST Osped Maggiore Crema, Med Oncol, Crema, Italy
[5] Univ Milan, Ctr Complex & Biosyst, Milan, Italy
[6] Univ Milan, Dept Environm Sci & Policy, Milan, Italy
[7] FPO IRCCS Candiolo, Candiolo Canc Inst, Sci Direct, Turin, Italy
[8] Univ Turin, Dept Med Sci, Turin, Italy
[9] Mario Negri Inst Pharmacol Res, Milan, Italy
[10] European Inst Oncol, Milan, Italy
关键词
moderate physical activity; breast cancer; cytokines; neoadjuvant chemotherapy; immune system; pathological complete response; EXERCISE; CYTOKINES; IMMUNITY;
D O I
10.1016/j.esmoop.2024.103665
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Physical activity (PA) reduces the risk of developing breast cancer (BC) and mortality rate in BC patients starting PA after diagnosis. Immunomodulation is considered responsible for these effects. However, limited data exist on the immunomodulation induced by moderate PA (mPA) during neoadjuvant chemotherapy (NACT). We have investigated the longitudinal change of cytokines during NACT alone or combined with mPA. Materials and methods: Twenty-three cytokines were analyzed in BC patients at consecutive timepoints: at baseline (T0), before starting mPA (T1), before surgery (T2), and after surgery (T3). mPA consisted of 3-weekly brisk-walking sessions for 9-10 consecutive weeks. Results: Ninety-two patients were assessed: 21 patients refused mPA (untrained) and 71 agreed (trained). At T1, NACT induced significant up-regulation of interleukin (IL)-5, IL-6, IL-15, chemokine ligand (CCL)-2, interferon-y, and C-X-C motif ligand (CXCL)-10 and reduction of expression of IL-13 and CCL-22. At T2, NACT and mPA induced upregulation of IL-21, CCL-2, and tumor necrosis factor-a and reduction of expression of IL-8, IL-15, vascular endothelial growth factor, and soluble interleukin 6 receptor. Only CXCL-10 increased in untrained patients. A cytokine score (CS) was created to analyze, all together, the changes between T1 and T2. At T2 the CS decreased in trained and increased in untrained patients. We clustered the patients using cytokines and predictive factors and identified two clusters. The cluster A, encompassing 90% of trained patients, showed more pathological complete response (pCR) compared to the cluster B: 78% versus 22%, respectively. Conclusions: mPA interacts with NACT inducing CS reduction in trained patients not observed in untrained patients, suggesting a reduction of inflammation, notwithstanding chemotherapy. This effect may contribute to the higher rate of pCR observed in the cluster A, including most trained patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Physical activity of breast cancer patients during chemotherapy
    Helbrich, H.
    Friese, K.
    Haertl, K.
    GYNAKOLOGE, 2019, 52 (01): : 69 - 80
  • [22] MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
    Goorts, Briete X. Z.
    Dreuning, Kelly M. A.
    Houwers, Janneke B.
    Kooreman, Loes F. S.
    Boerma, Evert-Jan G.
    Mann, Ritse M.
    Lobbes, Marc B. I.
    Smidt, Marjolein L.
    BREAST CANCER RESEARCH, 2018, 20
  • [23] Physical activity during and after adjuvant chemotherapy in patients with breast cancer
    Johnsson, Anna
    Johnsson, Anders
    Johansson, Karin
    PHYSIOTHERAPY, 2013, 99 (03) : 221 - 227
  • [24] Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
    Hong, Jin
    Rui, Weiwei
    Fei, Xiaochun
    Chen, Xiaosong
    Shen, Kunwei
    CANCER MEDICINE, 2021, 10 (22): : 7921 - 7933
  • [25] Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy
    Li, Fucheng
    Wang, Youyu
    Dou, He
    Chen, Xingyan
    Wang, Jianan
    Xiao, Min
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [26] Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
    Briete Goorts
    Thiemo J. A. van Nijnatten
    Linda de Munck
    Martine Moossdorff
    Esther M. Heuts
    Maaike de Boer
    Marc B. I. Lobbes
    Marjolein L. Smidt
    Breast Cancer Research and Treatment, 2017, 163 : 83 - 91
  • [27] Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer
    Meng, Xiangyu
    Wang, Xueying
    Jiang, Cong
    Zhang, Shuai
    Cheng, Shaoqiang
    TRANSLATIONAL ONCOLOGY, 2022, 18
  • [28] Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
    Inari, Hitoshi
    Teruya, Natsuki
    Kishi, Miki
    Horii, Rie
    Akiyama, Futoshi
    Takahashi, Shunji
    Ito, Yoshinori
    Ueno, Takayuki
    Iwase, Takuji
    Ohno, Shinji
    CANCERS, 2020, 12 (09) : 1 - 14
  • [29] Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
    Goorts, Briete
    van Nijnatten, Thiemo J. A.
    de Munck, Linda
    Moossdorff, Martine
    Heuts, Esther M.
    de Boer, Maaike
    Lobbes, Marc B. I.
    Smidt, Marjolein L.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (01) : 83 - 91
  • [30] Is the Neutrophil-to-Lymphocyte Ratio a Predictive Factor of Pathological Complete Response in Egyptian Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
    Ebaid, Naglaa F.
    Abdelkawy, Khaled S.
    Said, Amira S. A.
    Al-Ahmad, Mohamad M.
    Shehata, Mohamed A.
    Salem, Heba F.
    Hussein, Raghda R. S.
    MEDICINA-LITHUANIA, 2025, 61 (02):